Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 12 micrograms/hour - phenylpiperidine derivatives; fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 25 micrograms/hour - phenylpiperidine derivatives; fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 50 micrograms/hour - phenylpiperidine derivatives; fentanyl

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen sciences ireland uc - fentanyl - transdermal patch - 75 micrograms/hour - phenylpiperidine derivatives; fentanyl

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 16.8mg;   - transdermal patch - 100 mcg/h - active: fentanyl 16.8mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 2.1mg;   - transdermal patch - 12 mcg/h - active: fentanyl 2.1mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 4.2mg;   - transdermal patch - 25 mcg/h - active: fentanyl 4.2mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 6.3mg;   - transdermal patch - 37 mcg/h - active: fentanyl 6.3mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 8.4mg;   - transdermal patch - 50 mcg/h - active: fentanyl 8.4mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - fentanyl 12.6mg;   - transdermal patch - 75 mcg/h - active: fentanyl 12.6mg   excipient: durotak 87-4287 pegoterate   - the management of chronic cancer pain. the management of opioid-responsive chronic severe pain of non-malignant origin in opioid tolerant patients, after other conservative methods of analgesia have been tried. for use in accordance with nzma guidelines on chronic pain management and where there is no psychological contraindication, drug seeking behaviour or history of drug misuse.